These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38219868)

  • 1. Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.
    Kumar P; Krishna P; Nidoni R; Adarsh CK; Arun MG; Shetty A; Mathangi J; Sandhya ; Gopasetty M; Venugopal B
    Am J Transplant; 2024 Jun; 24(6):1087-1090. PubMed ID: 38219868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar Efficacy Between Atezolizumab Plus Bevacizumab
    Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
    In Vivo; 2024; 38(4):1854-1858. PubMed ID: 38936922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
    Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
    BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Zhu M; Liu Z; Chen S; Luo Z; Tu J; Qiao L; Wu J; Fan W; Peng Z
    Hepatology; 2024 Oct; 80(4):807-815. PubMed ID: 38358542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel concept of "sequential particle radiotherapy" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Komatsu S; Terashima K; Ishihara N; Matsuo Y; Kido M; Yanagimoto H; Toyama H; Tokumaru S; Okimoto T; Fukumoto T
    Surg Today; 2024 Aug; 54(8):972-976. PubMed ID: 38436718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year.
    Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
    Cancer Res Treat; 2024 Oct; 56(4):1231-1239. PubMed ID: 38810969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.
    Kurisaki K; Soyama A; Hara T; Matsushima H; Imamura H; Tanaka T; Adachi T; Ito S; Kanetaka K; Hidaka M; Okano S; Eguchi S
    Dig Surg; 2023; 40(1-2):84-89. PubMed ID: 36848877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
    Badhrinarayanan S; Cotter C; Zhu H; Lin YC; Kudo M; Li D
    Future Oncol; 2024; 20(28):2049-2057. PubMed ID: 38861301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis.
    Liu J; Qian J; Yang Z; Zhou L; Zheng S
    J Hepatol; 2024 May; 80(5):e219-e221. PubMed ID: 37939856
    [No Abstract]   [Full Text] [Related]  

  • 16. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review.
    Lin TY; Su TH
    J Formos Med Assoc; 2024 Aug; 123(8):916-919. PubMed ID: 38565487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to: "Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    Soin A; Lesurtel M; Clavien PA
    J Hepatol; 2024 May; 80(5):e222. PubMed ID: 38340810
    [No Abstract]   [Full Text] [Related]  

  • 19. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.
    Luo X; Chang RZ; Kuang D; Yuan M; Li GX; Zhang B; Wang YJ; Zhang WG; Ding ZY
    Front Immunol; 2023; 14():1285296. PubMed ID: 37928536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series.
    Sakaguchi K; Satoh T; Kawaguchi S; Aoyama T; Asahara K; Endo S; Shirane N; Kanemoto H; Oba N; Ohno K
    Clin J Gastroenterol; 2024 Jun; 17(3):515-522. PubMed ID: 38502472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.